11月23日晚间，青木科技公告称，公司拟以自有资金通过全资子公司 QINGMU PTE. LTD. （简称"青木新加坡"） 收购Vitalis的部分股权，交易完成后，公司将持有Vitalis65.8314%的股权。 长江商报消息●长江商报记者 徐阳 国内领先的互联网电商服务商青木科技（301110.SZ）推大额并购布局大健康，提升公司市场竞争力。 11月23日晚，青木科技公告，公司全资子公司将以2.12亿元现金通过老股转让及认购新股方式获得VitalisPharma AS（简称"Vitalis"）65.83%的股权，成为其控股股东。 青木科技称，本次并购主要是为了落实公司品牌孵化及管理业务发展战略，提升公司在健康食品领域的竞争力。 随着业务规模扩大，青木科技盈利稳步提升，2025年前三季度实现营业收入和归属于上市公司股东的净利润（简 称"归母净利润"）双增长，毛利率达56.33%，创同期新高。 拟2.12亿拿下Vitalis控制权 需要关注的是，Vitalis股权的收购价格为3.00亿挪威克朗（约合人民币2.12亿元），预计将形成较大金额商誉，存 在商誉减值风险。 青木科技表示，本次并购目的是落实公司品牌孵化 ...

证券日报网讯金河生物11月24日在互动平台回答投资者提问时表示，虾青素依托其极强的抗氧化能力， 可应用于保健食品、水产养殖、饲料、制药、化妆品等领域。公司的虾青素产品是与上海交大生命科学 技术学院签署战略合作后落地的首个合成生物学产品，该产品是红法夫酵母在发酵过程中的代谢产物， 与红海藻提取的天然虾青素均为左旋结构，同时较天然提取法产量高、成本低。目前，公司已建成年产 3000吨虾青素项目，相关产品饲料添加剂红法夫酵母已获得产品批准文号，目前正处于市场推广中。 （文章来源：证券日报） ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问公司的虾青素产品能应用到哪些领域？市场反响 怎么样？ 金河生物（002688.SZ）11月24日在投资者互动平台表示，虾青素依托其极强的抗氧化能力，可应用于 保健食品、水产养殖、饲料、制药、化妆品等领域。公司的虾青素产品是与上海交大生命科学技术学院 签署战略合作后落地的首个合成生物学产品，该产品是红法夫酵母在发酵过程中的代谢产物，与红海藻 提取的天然虾青素均为左旋结构，同时较天然提取法产量高、成本低。目前，公司已建成年产3000吨虾 青素项目，相关产品饲料添加剂红法夫酵母已获得产品批准文号，目前正处于市场推广中。 ...

Summary of Aoki Technology's Conference Call Company Overview - **Company**: Aoki Technology - **Acquisition Target**: Omega Brand - **Acquisition Amount**: Approximately 200 million RMB for 65.83% stake Key Points Industry and Market Potential - The health supplement industry in China is projected to reach a total market size of approximately 400 to 450 billion RMB in 2024, with an annual growth rate of 15% to 20% [6][12] - The fish oil segment is particularly strong, with online sales reaching 8.2 billion RMB from January to October 2025, representing a 36% year-on-year growth [6] Acquisition Details - Aoki Technology will acquire Omega Brand through a two-step process: purchasing existing shares and increasing capital, totaling 150 million Norwegian Krone (approximately 100 million RMB) [3][8] - The valuation is based on a 10.8 times price-to-earnings ratio for 2024 net profit, which is expected to become more attractive with a projected annual growth rate of over 35% [2][8] Financial Impact - The acquisition is expected to add over 500 million RMB to Aoki's annual profits, with a net profit margin anticipated to exceed 10% [2][9] - Aoki aims for Omega Brand to achieve over 1 billion RMB in revenue by 2027-2028, with a target of 35% growth compared to 2025 [4][12] Strategic Integration - Aoki plans to enhance Omega's supply chain, improve R&D capabilities, and expand into global markets [10] - The company will leverage existing online and offline channels, aiming for a balanced sales distribution between both [11] Product Development and Marketing - Aoki will focus on extending product lines around seal oil, fish oil, and astaxanthin, targeting cardiovascular health and expanding into brain health and eye care [11][16] - The company intends to utilize its marketing resources and consumer insights to support the new brand's growth [26] Competitive Advantages - Aoki has a strong position in the seal oil market due to its close relationships with upstream suppliers, which provides a competitive edge [13][15] - The company plans to differentiate itself in the health supplement sector by enhancing R&D for various products [15] Future Outlook - Aoki's current market share in China is approximately 80%, with plans to expand into Southeast Asia, Europe, and the Americas [14] - The company expects to see an increase in net profit margins as brand scale effects become more pronounced, with a projected net profit margin exceeding 25% [22][28] Operational Strategy - The new acquisition will be operated independently by Aoki's wholly-owned subsidiary, with expectations of significant revenue contributions in the coming years [24][25] - Aoki is also considering expanding into health food products in the long term, while focusing on existing supplement lines in the short term [17] Sales Performance - During the Double Eleven shopping festival, Aoki achieved a sales completion rate of over 100%, with a lower return rate compared to the previous year [23] This summary encapsulates the strategic direction, financial implications, and market positioning of Aoki Technology following its acquisition of Omega Brand, highlighting the company's growth potential in the health supplement industry.

Core Viewpoint - The company has developed astaxanthin products with strong antioxidant capabilities, applicable in various fields such as health food, aquaculture, feed, pharmaceuticals, and cosmetics [2]. Group 1: Product Applications - Astaxanthin can be utilized in health food, aquaculture, feed, pharmaceuticals, and cosmetics due to its strong antioxidant properties [2]. - The company's astaxanthin product is the first synthetic biology product developed in collaboration with Shanghai Jiao Tong University [2]. Group 2: Production and Market Status - The company has established an annual production capacity of 3,000 tons of astaxanthin [2]. - The feed additive derived from red yeast has received product approval and is currently in the market promotion phase [2].

Core Viewpoint - The company, Jinhe Biology, is leveraging its astaxanthin product, which has strong antioxidant properties, for applications in health food, aquaculture, feed, pharmaceuticals, and cosmetics [1] Group 1: Product Development - The astaxanthin product is the first synthetic biology product developed in collaboration with Shanghai Jiao Tong University School of Life Sciences [1] - The product is a metabolic byproduct of red yeast during fermentation, with a structure similar to natural astaxanthin extracted from red algae [1] - The synthetic method offers higher yield and lower cost compared to natural extraction methods [1] Group 2: Production Capacity - The company has established an annual production capacity of 3,000 tons for astaxanthin [1] - The feed additive product derived from red yeast has received product approval and is currently in the market promotion phase [1]

Key Points - MSCI announced the inclusion of 26 new Chinese stocks and the removal of 20 stocks from the MSCI China Index, effective after the market close on November 24, 2025 [2] - The Ministry of Finance and the People's Bank of China have included electronic savings bonds in the scope of personal pension products to support the development of a multi-tiered pension insurance system [3] - Sixteen hard technology-themed funds have been approved, including seven AI ETFs and three chip ETFs, indicating an influx of capital into the sector [4] - The first large-capacity all-solid-state battery production line in China has been completed, with plans for small-scale production tests and a target for mass production between 2027 and 2030 [5] - Alibaba and Meituan are set to release their financial reports on November 25 and November 28, respectively, along with reports from leading electric vehicle companies [6][7] - The Federal Reserve will release its Beige Book this week, with expectations of interest rate decisions from New Zealand and South Korea [8] Company News - Hillstone Networks expects to achieve large-scale sales and product delivery of its new generation security products equipped with ASIC chips by Q1 2026 [10] - Zhongjin Lingnan plans to acquire a 6.7784% stake in Zhongjin Copper and a 10.3333% stake in Zhongjin Rongsheng for a total consideration of 742 million yuan [11] - Jinfeng Technology is planning to acquire at least a 51% stake in Guangdong Lanyuan Technology, which will enhance its growth and profitability [12] - Nenghui Technology signed a contract for a new energy power battery assembly with an estimated total price of 100 million yuan [13] - JinkoSolar announced the mass production of its Tiger Neo 3.0 module, achieving a production efficiency of over 24.8% and a total order of 15 GW [14] - Qingmu Technology's subsidiary plans to acquire control of Vitalis, enhancing its competitiveness in the health supplement sector [16] - Jiahua Technology is planning to acquire a controlling stake in Shudun Technology, with stock suspension expected [17] Market Insights - China Merchants Securities maintains a cautious outlook, citing weak trading signals and mixed fundamental indicators [19] - CITIC Securities notes the market is in a "three-phase overlap," suggesting a wait-and-see approach until key economic meetings in December [20]

Core Viewpoint - Qingmu Technology (301110) is expanding its business through a significant acquisition, aiming to enhance its brand incubation and management strategy in the health and wellness sector [1][4]. Group 1: Acquisition Details - Qingmu Technology's subsidiary, Qingmu Singapore, signed a share purchase and subscription agreement to acquire 49.07% of the target company's shares from Norsund for 150 million Norwegian Krone (approximately 106 million RMB) and to subscribe for an additional 32.92% of new shares for the same amount [1]. - After the completion of this transaction, Qingmu Singapore will hold a total of 65.83% of the target company, becoming its controlling shareholder, and the target company will be included in Qingmu's consolidated financial statements [1]. Group 2: Business Model and Services - Qingmu Technology provides comprehensive e-commerce services, including e-commerce operation, channel distribution, and retail services, catering to well-known domestic and international brands [1][2]. - The company has established a complete e-commerce ecosystem, collaborating with major platforms such as Tmall, JD.com, Douyin, Xiaohongshu, and Vipshop, and offers a full range of services from traditional e-commerce operations to digital marketing and consumer engagement [2]. Group 3: Growth Strategy - The brand incubation and management business is identified as the company's second growth curve, with a focus on health consumer products. The company plans to invest more in this area and introduce overseas quality brands through various methods, including joint ventures and acquisitions [3]. - The company reported significant revenue growth for its incubated brands, with Cumlaude Lab and ZUCCARI achieving over 70% and 95% year-on-year growth, respectively, in the first half of 2025 [3]. Group 4: Future Outlook - The acquisition aims to strengthen the company's capabilities in brand management, research and development, production, and supply chain management in the health supplement sector, enhancing its competitive edge [4]. - Qingmu Technology aspires to become a "data and technology-driven retail service expert," focusing on the application of new technologies like AI to improve operational efficiency [3].

以下是第一财经对一些重要公告的汇总，供投资者参考。 【品大事】 佳华科技：拟购买数盾科技控股权 股票停牌 佳华科技公告，公司正在筹划以发行股份及支付现金的方式购买数盾信息科技股份有限公司的控股权并 募集配套资金，可能构成重大资产重组。公司股票自2025年11月24日起停牌，预计停牌时间不超过5个 交易日。 招商银行：招银金融资产投资有限公司获准开业 招商银行公告，全资子公司招银金融资产投资有限公司已获金融监管总局批准开业。该公司注册资本为 150亿元，将开展市场化债转股业务及股权投资试点业务。 中信银行：全资子公司信银金投获准开业 中信银行公告，国家金融监管总局已批准全资子公司信银金融资产投资有限公司（简称"信银金投"）开 业。信银金投注册资本为100亿元，注册地为广东省广州市。信银金投将围绕战略新兴产业、"专精特 新"等重点领域，开展市场化债转股及股权投资业务。 中水渔业：公司股价存在大幅上涨后回落风险 中水渔业公告，公司股票连续两个交易日收盘价涨幅偏离值累计超过20%。公司最新滚动市盈率77.53 倍，市净率为13.48倍，公司当前的市盈率、市净率与同行业平均水平有较大差异。公司近期股票交易 异常波动，可 ...

标的公司主要从事高端健康营养补充剂的研发、生产及销售，旗下拥有Noromega等品牌，主要产品包 括海豹油、鱼油、虾青素、辅酶Q10等系列产品。本次并购目的是落实公司品牌孵化及管理业务发展战 略，加强公司在大健康赛道的布局和竞争力。本次交易完成后，将增强公司在品牌管理、健康营养补充 剂产品的研发、生产及供应链管理等方面的综合能力，并补充公司旗下自有品牌，以及公司的全资子公 司将成为Noromega品牌的中国区总经销商，将有利于提升公司的持续盈利能力。 智通财经APP讯，青木科技(301110.SZ)发布公告，公司的全资子公司QINGMU PTE.LTD.(简称"青木新 加坡")与Norsund Gruppen AS(简称"Norsund")、YunlinZHAN签署《股份购买及认购协议》，与 Norsund、Yunlin ZHAN及Vitalis Pharma AS(简称"Vitalis"或"标的公司")签署《新股认购协议》，以及相 关附属协议(《股份购买及认购协议》、《新股认购协议》及相关附属协议合称"收购协议")。根据收购 协议，青木新加坡将以1.5亿挪威克朗(约合人民币1.06亿元)现金购买Norsun ...